Summary Urine from cancer patients with weight loss showed the presence of an antigen of Mr 24 000 detected with a monoclonal antibody formed by fusion of splenocytes from mice with cancer cachexia. The antigen was not present in the urine of normal subjects, patients with weight loss from conditions other than cancer or from cancer patients who were weight stable or with low weight loss (1 kg month-1). The antigen was present in the urine from subjects with carcinomas of the pancreas, breast, lung and ovary. The antigen was purified from urine using a combination of affinity chromatography with the mouse monoclonal antibody and reversed-phase high-performance liquid chromotography (HPLC). This procedure gave a 200 000-fold purification of the protein over that in the original urine extract and the material isolated was homogeneous, as determined by silver staining of gels. The N-terminal amino acid sequence showed no homology with any of the recognized cytokines. Administration of this material to mice caused a significant (P<0.005) reduction in body weight when compared with a control group receiving material purified in the same way from the urine of a normal subject. Weight loss occurred without a reduction in food and water intake and was prevented by prior administration of the mouse monoclonal antibody. Body composition analysis showed a decrease in both fat and non-fat carcass mass without a change in water content. The effects on body composition were reversed in mice treated with the monoclonal antibody. There was a decrease in protein synthesis and an increase in degradation in skeletal muscle. Protein degradation was associated with an increased prostaglandin E2 (PGE2) release. Both protein degradation and PGE2 release were significantly reduced in mice pretreated with the monoclonal antibody. These results show that the material of Mr 24 000 present in the urine of cachectic cancer patients is capable of producing a syndrome of cachexia in mice.
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Keywords: cachectic factor; cancer patients; glycoprotein; protein degradation Progressive weight loss is a common feature of many types of cancer and is particularly prominent in patients with carcinomas of the pancreas and stomach (DeWys et al, 1980) . The degree of expression of cachexia varies, even among patients with identical stage and tumour histology, and bears no simple correlation to tumour burden, tumour cell type or anatomical site of involvement (Costa, 1977) . Although anorexia frequently accompanies cachexia, there is some evidence to suggest that it may develop after weight loss as a result of nausea associated with disease progression (Warnold et al, 1978) . In addition, studies with total parenteral nutrition indicate that many patients either maintain body weight or lose weight while receiving calories, which would be predicted to result in weight gain (Heber et al, 1986) . This suggests that decreases in food intake alone may be insufficient to account for cachexia and that cachexia-inducing factors may be produced by some tumour types.
Most research effort has focused on the role of cytokines as mediators of the process of cachexia, particularly tumour necrosis factor alpha (TNF-a) and interleukin 6 (IL-6). Implantation into mice of Chinese hamster ovary (CHO) cells transfected with the gene for TNF-a produces a syndrome resembling cancer cachexia with progressive wasting, anorexia and early death (Oliff et al, the requirement for high levels of TNF-a to induce cachexia in experimental models. Even in some cancer patients in whom elevated levels of TNF-a may be present, this does not seem to be correlated with the presence of cachexia (Balkwill et al, 1987; Saarinen et al, 1990) . Although CHO cells transfected with the IL-6 gene have been shown to produce a syndrome of cachexia in nude mice (Black et al, 1991) , cachexia is not observed in patients with IL-6-producing tumours, at least during the early stage of tumour growth (Ishibashi et al, 1993) . In addition, serum levels of IL-6 have been found to increase to similar levels in two clones of colon 26 adenocarcinoma, although only one produced the syndrome of cachexia when transplanted into syngenic mice (Soda et al, 1994) . These results suggest that other factors may contribute to the development of cachexia.
We have recently described a proteoglycan of Mr 24 000, detected by Western blotting using serum from mice bearing a cachexia-inducing tumour (MAC 16) , that was present in the urine of patients with cancer cachexia, but absent from the urine of normal subjects (McDevitt et al, 1995; Todorov et al, 1996a) . The material was not detected using serum from mice bearing a related tumour (MAC 13) that does not induce cachexia. Intravenous administration of the proteoglycan purified from the MAC 16 tumour into non-tumour-bearing mice produced a state of cachexia with rapid loss of body mass (Todorov et al, 1996a) . This study documents the isolation of a similar material of Mr 24 000 from the urine of cachectic cancer patients by affinity chromatography 
Western blotting
Urine (20 ml) was treated with ammonium sulphate (80%, w/v) and stirred overnight at 4°C. The precipitated protein was recovered by centrifugation at 3 000 g for 30 min, dialysed against water through an Amicon filtration cell containing a membrane filter with a molecular weight cut-off of 10000 and concentrated. Samples (5 jig) were loaded on sodium dodecylsulphate polyacrylamide gels, prepared according to the method of Laemmli (1970) and consisted of a 5% stacking gel and a 15% resolving gel. For immunoblotting, gels were transferred to nitrocellulose membranes (Hoefer Scientific Instruments, San Francisco, CA, USA); which had been blocked with 5% Marvel in 0.15% Tween-20 in phosphate-buffered saline (PBS) at 4°C overnight. The membranes were washed once for 15 min in 0.5% Tween-20 in PBS, followed by two more washes for 5 min in Tween/PBS. The membranes were further incubated for 1 h at room temperature in Tween/PBS containing 1.5% Marvel and 10 jig ml-' of the monoclonal antibody, prepared as described (Todorov et al, 1996b) , and which had been biotinylated using the ECL protein biotinylation module (Amersham, UK). After being washed three times as above, the filters were incubated for 1 h at room temperature with streptavidin-horseradish peroxidase conjugate (Amersham) at a 1-to 1500-fold dilution followed by three 15 min washes with 0.1% Tween in PBS. Bands were detected with an emission chemiluminescence (ECL) system (Amersham).
using a monoclonal antibody produced by fusion of splenocytes from mice bearing the MAC16 tumour with BALB/C myeloma cells, and screened for antibodies to the Mr 24 000 material (Todorov et al, 1996b) . The role of this material in cancer cachexia has now been evaluated.
MATERIALS AND METHODS

Subjects
Twenty-four-hour urine collections were made from normal subjects (12), in-hospital patients who were losing weight through causes other than cancer (24) (Table 1A) , whereas lanes 2-4 represent urine obtained from normal subjects numbers 6, 7 and 9 respectively ( (Table 1A) (lanes 1-3) and weight-losing non-cancer patients numbers 3, 2 and 1 ( (Todorov et al, 1996b) , were pooled and the volume was reduced by ultrafiltration against water in an Amicon filtration cell. Portions (50 gl) were fractionated using reversed-phase hydrophobic chromatography with a Brownlee Aquapore RP-300 C8 column (Applied Biosystems), size 100 x 2.1 mm. The flow rate was 0.2 ml min-' with solvent system A [HPLC grade water (Fisons, Loughborough, UK) plus 0.06% trifluoroacetate (TFA)] or B [acetonitrile 190, Romil Chemicals, Loughborough, UK) plus 0.04% TFA]. The gradient was 2-65% B in A over a 30 min period followed by 65-100% B in A over 10 min and 100% B for 10 min. Absorbance was monitored at 214 nm.
Tyrosine-release assay
Mice were injected i.v. with the affinity-purified material (150 pl x 4) and after 24 h the soleus muscles were ligated by the tendons, dissected out intact and placed in ice-cold isotonic saline. They were then quickly ligated to stainless-steel supports under slight tension, which resembled that observed at resting length in vivo, and incubated for 2 h in Krebs-Henseleit buffer containing 6 mm D-glucose, 1.2 mg ml-' bovine serum albumin and 130 tg ml-' cycloheximide with continuous gassing. At the end of the incubation, the buffer was removed, deproteinized with ice-cold 30% trichloroacetic acid (0.2 ml), centrifuged at 2800 g for 10 min and the supernatant was used for the measurement of tyrosine by a fluorimetric method (Waalkes and Udenfriend, 1957) at 570 nm on a Perkin-Elmer LS-5 luminescence spectrometer.
Prostaglandin E2 determination
A portion (100 ,l) of the soleus muscle incubation medium was mixed with [5,6,8,11,12,14,15-3H(N) ]-prostaglandin E2 (0.1 ,Ci; sp. act. 154 Ci mmol-') (Amersham) and PGE2 rabbit antiserum (Sigma Chemical, Poole, Dorset UK) (for the particular batch a 1:20 dilution was used to give 40% binding of [3H]PGE2 in 100 gl) in Eppendorf tubes, vortexed and incubated for 1 h at 37°C. Samples were then kept at 4°C for 5 min and a mixture of ice-cold dextran charcoal (500 pl) was added and allowed to stand for 15 min at 4'C. Bound and unbound material were separated by centrifugation (2000g for 10 min at 4°C) and the concentration of PGE2 was determined from standard curves prepared on the same day.
Determination of protein synthesis in organs Mice were administered 0.25 ml of physiological saline containing 0.4 mM L-[4-3H]phenylalanine (15.6 , uCi) by i.p. injection together with i.v. injections of affinity-purified urine. Twenty-four hours after isotope injection, the animals were killed by cervical dislocation and the organs were removed and weighed and homogenized in 2% perchloric acid (4 ml). The homogenate was centrifuged at 2800 g for 15 min and the supematant was converted to a pH close to 6 by the addition of 1-5 ml of saturated tripotassium citrate. The insoluble potassium perchlorate was removed by centrifugation at 2800 g for 15 min and 1 ml of the supernatant was diluted (1:1) and added to 10 ml of Optiphase Hi-safe 3 scintillation fluid (FSA Laboratory Supplies, Loughborough, UK) for the measurement of 1995) . Hybridomas have now been produced using splenocytes from mice transplanted with the MAC16 tumour and cloned to produce antibodies recognizing the mouse Mr 24 000 material (Todorov et al, 1996b) . Western blots of an 80% ammonium sulphate precipitate of whole urine, using the mouse monoclonal antibody, showed evidence for similar immunoreactive material of Mr 24 000 in the urines of cancer patients with weight loss ( Figure  IA ). Such immunoreactive material was not present in the urine of 12 normal subjects tested ( Figure 1B) . Thus, patients with pancreatic, lung, colon, breast, rectal, liver, ovarian and cholangiocarcinoma, in whom the rate of weight loss was greater than or equal to about 1.0 kg month-' showed evidence of excretion of the Mr 24 000 material. Patients who were weight stable or in whom the rate of weight loss was equal to or less than 1.0 kg month-' showed no evidence of such excretion. To gain more information on the nature and function of the Mr 24 000 substance, urine from cachectic cancer patients that was positive by Western blotting was purified by a combination of affinity chromatography and reversed-phase HPLC (Table 4) . The procedure for affinity chromatography involved an initial ammonium sulphate precipitation of urine, which was then applied to a column of Affi-gel Hz, containing bound mouse monoclonal antibody. Bound material was eluted with glycine-HCl, pH 2.5, and the immonoreactive fractions, determined by Western blotting (Figure 2A) , represented only 0.12% of the protein present in the ammonium sulphate precipitate, giving a 168-fold purification. Further fractionation of immunoreactive material was achieved using reversed-phase hydrophobic chromatography on a C8 column, with an acetonitrile and water gradient. The immunoreactive fraction eluted at 56% acetonitrile as determined by Western blotting ( Figure 2B ) and was present as a single component as determined by silver staining of gels ( Figure 2C ). The protein recovery at this step was 5 x 104%, representing almost a 200 000-fold purification from the ammonium sulphate precipitate (Table 4 ). The material stained heavily for carbohydrate as determined by the digoxigenin glycan detection kit (Amersham). The N-terminal amino acid sequence of this material is shown in Table  5 and has no homology with any of the recognized cytokines, but British Journal of Cancer (1997) 76(5) is homologous to material of Mr 24 000 from the MAC 16 tumour (Todorov et al, 1996a,b) . To investigate the biological effects of the immunoreactive material from cancer patients' urine, mice were treated by i.v. injection and the effect on body weight and food and water intake was monitored over a 24-h period. The results depicted in Figure 3 show a significant (P < 0.005) reduction in the body weight of Time (h) Figure 3 Effect of purified urine extract on body weight of female NMRI mice (average weight 19 g). Material purified from urine of patient 4 (150 ,ul; 1 ,ug protein) were injected into the tail vein of five female NMRI mice at 1.5-h intervals (10.30, 12.00, 13.30 and 15.00 h) and body weight was monitored over a 24-h period (*). Control animals (A) received material purified from the urine of normal subjects, whereas the third group received monoclonal antibody (two injections of 0.4 mg of protein in 250 tli of PBS by i.p. injection) 24 h before the first injection of the purified cachectic urine extract (U). The results are means ± s.e.m. for five mice per group and the experiment was repeated five times. At 24 h the body weight of mice receiving the cachectic urine was significantly different (P < 0.0005) from that of the control group as determined using an unpaired Student's t-test. Body weight in the mice pretreated with the monoclonal antibody was significantly different (P < 0.05) from that of the untreated group. Both food and water intake were monitored during the course of the experiment mice receiving material purified from the urine of a cachectic cancer patient when compared with a control group receiving material purified in the same way from a normal subject. Weight loss occurred without an effect on food (3.3 g per mouse) and water (3.2 ml per mouse) intake compared with controls (3.5 g per mouse and 3.5 ml per mouse respectively). Pretreatment with the mouse monoclonal antibody completely reversed the decrease in body weight, showing the specificity of the human immunoreactive material (Figure 3) . Analysis of individual body organs showed a significant decrease in soleus muscle (from 7 ± 0.2 mg to 5 ± 0.4 mg; P < 0.025) and kidney weight (from 250 ± 2 mg to 220 ± 1 mg; P < 0.05). Body composition analysis showed a small decrease in total body fat and a significant decrease in total carcass non-fat dry weight without a change in water composition (Table  6 ). The effects on fat and non-fat carcass mass were reversed in animals pretreated with the monoclonal antibody. Analysis of aAll values are given as mean + for five animals per group. Body composition analysis was performed as described (Beck and Tisdale, 1987) (g3) and degradation (-) in mouse gastrocnemius muscle 24 h after the administration of either purified normal human urine extract (control) or extract from the urine of a cachectic cancer patient (treated). Protein degradation was measured by the release of [4-3H] phenylalanine as previously described (Smith and Tisdale, 1993a) .
(B)
Protein synthesis rates in heart (C), liver (P2), spleen (E) and kidney (-) 24 h after administration of the purified cachectic urine extract. Control mice received material purified from the urine of normal subjects. Differences from control group are indicated as ap < 0.05 and bp < 0.01 using Student's t-test plasma metabolite levels (Table 6 ) showed a significant decrease in blood glucose, 3-hydroxybutyrate and triglyceride levels and an increase in non-esterified fatty acids after treatment with the human Mr 24 000 proteoglycan. The effects on 3-hydroxybutyrate and triglyceride levels were reversed by the monoclonal antibody.
The effect on protein synthesis in the individual organs is shown in Figure 4 . Treatment with the cachectic urine extract caused a significant decrease in protein synthesis in gastrocnemius muscle and an increase in protein degradation, as measured by the release of [3H]phenylalanine ( Figure 4A ). Of the other organs, only heart showed a significant decrease in protein synthesis ( Figure 4B ). Protein degradation in soleus muscle was also significantly increased as determined by tyrosine release ( Figure 5A ). The increased protein degradation was correlated with an increased prostaglandin E2 (PGE2) release ( Figure SB) . Both protein degradation and PGE2 release in soleus muscle were significantly inhibited in mice pretreated with the monoclonal antibody. These results suggest that the material of Mr 24 000 present in the urine of cachectic cancer patients may be responsible for the weight loss by producing an increased protein degradation in skeletal muscle.
DISCUSSION
The first suggestion that cancer cachexia may be mediated by a tumour product came from studies of Krebs-2 carcinoma cells in mice, which showed that weight loss and, in particular, fat depletion could be induced with non-viable preparations of the tumour (Costa and Holland, 1966) . Further evidence for a humoral mediation came from two sources. In a parabiotic pair of rats, one of which bore a cachexia-inducing sarcoma, the parabiotic tumour-free mouse also developed cachexia, despite the absence of metastasis (Norton et al, 1985) . In addition, serum from lymphoma-bearing mice, when injected into normal mice, produced an immediate fat mobilization that was not affected by feeding (Kitada et al, 1980) . Our search for a cachexia-inducing substance has been facilitated by the use of a murine model system, the MAC 16 colon adenocarcinoma. Animals bearing this tumour have elevated plasma levels of both lipolytic and proteolytic factors, which may be responsible for the cachexia (Beck and Tisdale, 1987) . During the purification of a lipid-mobilizing factor from this tumour, it was observed that some animals with a delayed weight loss contained in their serum antibodies that recognized a component of Mr 24 000 on Western blots (McDevitt et al, 1995) . This material co-purified with the lipid-mobilizing factor. Recently, we have described the production of a monoclonal antibody to this mouse material by fusion of splenocytes from mice transplanted with the MAC 16 tumour with myeloma cells (Todorov et al, 1996b) . Material isolated from the MAC 16 tumour by affinity chromatography also had Mr 24 000 and was capable of inducing protein degradation in isolated gastrocnemious muscle and of producing loss of body weight in vivo (Todorov et al, 1996a) .
The mouse monoclonal antibody was capable of recognizing a similar immunoreactive band of M 24 000 in the urine of cancer patients with active weight loss. Such material was not detected in the urine of normal subjects or cancer patients who were weight stable or who had minimal weight loss. In addition, patients losing weight through conditions other than cancer, such as major surgery, sepsis, multiple injuries, burns, acute pancreatitis, coeliac disease or sleeping sickness, had no evidence of the presence of the immunoreactive material of Mr 24 000 in the urine. This suggests that this material is specific to cancer cachexia and that cachexia in other conditions is mediated by other factors. Weight loss in sleeping sickness caused by trypanosome infection has been attributed to TNF-ax (Beutler et al, 1985) , whereas severe weight loss associated with thermal injury has been attributed to a combination of hypermetabolism, possibly due to elevated catecholamines, and inadequate caloric intake (Gump and Kinney, 1971) . Although the majority of the cancer patients we studied had pancreatic carcinoma, the presence of immunoreactive material of Mr 24 000 was not confined to this tumour type. A previous study (Belezario et al, 1991) has shown serum from cancer patients with weight loss to contain a material capable of inducing proteolysis in skeletal muscle. Such material was not found in healthy subjects. The nature of this material is not known. Another study reported a substance of Mr 5000 in urine from cachectic cancer patients and which was capable of causing lipid mobilization (Kitada et al, 1981) . However, this is the first report of a substance of Mr 24000 in the urine of cachectic cancer patients with significant biological activity.
Using the mouse monoclonal antibody, we have isolated, purified and partially sequenced the substance of Mr 24 000. Initial studies show that it is either a glycoprotein or a proteoglycan and that the sequence is homologous to a substance isolated from the MAC 16 tumour (Todorov et al, 1996a) . This suggests that the two substances are identical. Intravenous injection of this substance in mice causes a state of cachexia similar to that observed after administration of the murine material (Todorov et al, 1996a) in mice bearing the MAC16 tumour in that (a) weight loss occurs without a reduction in food and water intake (Beck and Tisdale, 1987) and thus is not due to toxicity of the material, (b) weight loss can be attenuated by prior administration of the monoclonal antibody, (c) there is marked hypoglycaemia (McDevitt and Tisdale, 1992) and (d) there is a decreased level of plasma triglycerides; in the last respect the effect is unlike that of TNF-a, which causes an increase (Mahony et al, 1988) . This observation, together with the finding of decreased plasma levels of 3-hydroxybutyrate, suggests that energy expenditure may be increased. In mice bearing the -MAC16 tumour, there is a gradual increase in rates of oxygen consumption and carbon dioxide production with increasing weight loss and an increase in energy expenditure leading to a negative energy balance (Plumb et al, 1991) . In this respect, the MAC16 tumour is similar to some human tumours in which the energy intake is not sufficient to meet the demands of an increased energy expenditure (Hyltander et al, 1991) . Administration of the human immunoreactive material of Mr 24 000 produces a depression in protein synthesis and an increased protein degradation in skeletal muscle, as measured by tyrosine release. Tyrosine is not metabolized in skeletal muscle and represents a suitable indicator of protein balance. We have previously reported that cachectic mice bearing the MAC 16 tumour also show reduced protein synthesis and increased protein degradation in skeletal muscle and, moreover, that this effect can be mimicked by serum from cachectic animals (Smith and Tisdale, 1993a) . In cancer patients, depletion of lean body mass has been attributed to depressed protein synthesis (Rennie et al, 1983; Emery et al, 1984) , increased protein degradation (Levin et al, 1983) or generally increased whole-body protein turnover (Kien and Camitta, 1983; O'Keefe et al, 1990) . The increased tyrosine release in isolated soleus muscle from mice treated with the human immunoreactive material has been correlated with an increased PGE2 release. Abrogation of weight loss by the mouse monoclonal antibody was associated with both reduced tyrosine release and reduced PGE2 production by soleus muscle. Previous studies (Smith and Tisdale, British Journal of Cancer (1997) 76 (5), 606-613 . Cancer Research Campaign 1997 Induction of cachexia by a human tumour product 613 1993b) have also found increased PGE2 production in isolated gastrocnemius muscle when incubated with serum from cachectic mice. Inhibition of the rise in PGE2 also inhibited muscle protein degradation. Other studies have also implicated PGE2 as a mediator of muscle protein degradation (Rodeman and Goldberg, 1982; Strelkov et al, 1989) , although other factors may also be involved. The mechanism by which the material of Mr 24 000 from cancer patient urine induces PGE2 release or inhibits protein synthesis in skeletal muscle is not known.
These results show that urine from patients with cancer cachexia contains an immunoreactive substance that is capable of producing in mice a syndrome resembling that of cancer cachexia. Preliminary structural studies suggest that this material has a novel structure that appears to be identical to that isolated from a cachexia-inducing murine tumour and is distinct from that of the recognized cytokines. Further structural studies are required to characterize this material ACKNOWLEDGEMENT This work was supported by Cancer Research Campaign Grant SP 1518.
